Literature DB >> 35602841

Thrombotic Thrombocytopenic Purpura: A Rare Cause of Severe Acute Kidney Injury.

Hatem Najar1, Laurene Tuider1, Vinita Kukkar2, Mohammad Quasem3.   

Abstract

Thrombotic microangiopathy (TMA) is a serious and potentially fatal disorder, especially if there is a delay in diagnosis and appropriate treatment. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are the two main forms of TMA. Although severe acute kidney injury (AKI) is a common manifestation of TMA, it remains rarely described in reported TTP cases. We present a rare case of TTP in a 76-year-old African American male who presented with severe AKI (stage 3) and uremic symptoms. Early diagnosis and prompt treatment of TTP with plasmapheresis followed by rituximab and caplacizumab were associated with the resolution of the AKI and avoidance of hemodialysis. This case highlights the need to consider TTP as a possible diagnosis even in the setting of severe AKI.
Copyright © 2022, Najar et al.

Entities:  

Keywords:  acute kidney injury; therapeutic plasmapheresis; thrombocytopenia; thrombotic microangiopathy (tma); thrombotic thrombocytopenic purpura

Year:  2022        PMID: 35602841      PMCID: PMC9113771          DOI: 10.7759/cureus.24221

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  7 in total

Review 1.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

Review 2.  Syndromes of thrombotic microangiopathy.

Authors:  James N George; Carla M Nester
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

3.  Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity.

Authors:  L Zafrani; E Mariotte; M Darmon; E Canet; S Merceron; D Boutboul; A Veyradier; L Galicier; E Azoulay
Journal:  J Thromb Haemost       Date:  2015-01-29       Impact factor: 5.824

Review 4.  Thrombotic Microangiopathy and the Kidney.

Authors:  Vicky Brocklebank; Katrina M Wood; David Kavanagh
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 8.237

5.  Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients.

Authors:  Thomas Raife; Bonnie Atkinson; Robert Montgomery; Sara Vesely; Kenneth Friedman
Journal:  Transfusion       Date:  2004-02       Impact factor: 3.157

6.  The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.

Authors:  E H Phillips; J P Westwood; V Brocklebank; E K S Wong; J O Tellez; K J Marchbank; S McGuckin; D P Gale; J Connolly; T H J Goodship; D Kavanagh; M A Scully
Journal:  J Thromb Haemost       Date:  2016-01-11       Impact factor: 5.824

7.  Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Dustin J Little; Lauren M Mathias; Evaren E Page; Johanna A Kremer Hovinga; Sara K Vesely; James N George
Journal:  Kidney Int Rep       Date:  2017-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.